Wells Fargo & Company Aura Biosciences, Inc. Transaction History

Wells Fargo & Company

$433 Billion
Q4 2024

A detailed history of Wells Fargo & Company transactions in Aura Biosciences, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 27,623 shares of AURA stock, worth $206,896. This represents 0.0% of its overall portfolio holdings.

Number of Shares

27,623

Previous 21,693 27.34%

Holding current value

$206,896

Previous $193,000 17.62%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 12, 2025	BUY	$8.11 - $11.74 $48,092 - $69,618	5,930 Added 27.34%	27,623 $227,000
Q3 2024 Nov 13, 2024	BUY	$6.9 - $10.36 $6,306 - $9,469	914 Added 4.4%	21,693 $193,000
Q2 2024 Aug 13, 2024	BUY	$6.81 - $7.89 $52,872 - $61,257	7,764 Added 59.65%	20,779 $157,000
Q1 2024 May 10, 2024	BUY	$7.09 - $9.24 $31,188 - $40,646	4,399 Added 51.06%	13,015 $102,000
Q4 2023 Feb 09, 2024	BUY	$7.02 - $11.98 $12,923 - $22,055	1,841 Added 27.17%	8,616 $76,000
Q3 2023 Nov 13, 2023	SELL	$8.97 - $12.38 $32,785 - $45,248	-3,655 Reduced 35.04%	6,775 $60,000
Q2 2023 Aug 15, 2023	BUY	$8.51 - $13.33 $49,945 - $78,233	5,869 Added 128.68%	10,430 $128,000
Q1 2023 May 12, 2023	BUY	$8.88 - $12.11 $40,501 - $55,233	4,561 New	4,561 $42,000
Q3 2022 Nov 14, 2022	SELL	$13.1 - $20.34 $1,572 - $2,440	-120 Reduced 27.91%	310 $6,000
Q2 2022 Aug 12, 2022	SELL	$12.37 - $21.86 $9,784 - $17,291	-791 Reduced 64.78%	430 $6,000
Q1 2022 May 16, 2022	SELL	$15.94 - $23.34 $32,629 - $47,776	-2,047 Reduced 62.64%	1,221 $27,000
Q4 2021 Feb 14, 2022	BUY	$14.76 - $24.89 $48,235 - $81,340	3,268 New	3,268 $55,000

Others Institutions Holding AURA

# of Institutions

Shares Held

39.9M

Call Options Held

1.9K

Put Options Held

31K

View Full List

About Aura Biosciences, Inc.

Ticker AURA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,273,600
Market Cap $219M
Description
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develop...

More about AURA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Aura Biosciences, Inc. Transaction History